Less than a day into his second term, President Donald Trump ordered a freeze on communications at major public health agencies, among other moves that have sent waves through the biopharma industry.
The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% ...
The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...
The San Diego–based company’s molecules avoid the well-trod GLP-1 pathway in favor of an alternate route in the gut.
The settlement is the largest deal to date with the people primarily who played an “instrumental role” in driving the opioid ...
Robert F. Kennedy, Jr.’s recent disclosures have revealed several potential conflicts of interest, including investments in ...
On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...
Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially ...
Protein degradation–focused Neomorph nabs its third Big Pharma deal of around $1.5 billion in less than a year.
In a good-news-bad-news week for Biogen, the company will cut an undisclosed number of employees, just as a higher dose of ...
Looking for a biopharma job in New Jersey? Check out the BioSpace list of eight companies hiring life sciences professionals ...
M&As are stressful for multiple reasons, including role changes and getting laid off when staffs combine. Two talent experts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback